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Bisphenol A [2,2-bis(4-hydroxyphenyl)
propane] (BPA) is used in industry as a
monomer for the synthesis of polycarbonate
plastics and epoxy resins. Polycarbonate plas-
tics are employed to manufacture various
materials that come in contact with human
food, such as plastic bottles, food containers,
and storage and microwave plastic ware.
Epoxy resins are used as a polymeric binder in
protective inner coatings of food and bever-
age cans (1,2). Unreacted BPA monomers are
released from these matrices and migrate into
food or beverages (1,3,4). Similarly, compos-
ites and sealants used in dentistry release BPA
monomers into saliva (5). BPA can also leach
from plastic-containing hazardous waste land-
fills (6). Although the biodegradation half-
lives of BPA in rivers and wastewater
treatment plants have been estimated as less
than 2 and 4 days, respectively (7,8), trace
amounts of BPA have been detected in drink-
ing water (9). Given these parameters, human
exposure to trace amounts of BPA is expected
to be relatively low but of daily occurrence.
Adverse effects of BPA on human and
animal reproduction are suspected, because it
is now well established that BPA is an estro-
genic chemical (10,11) able to interact with
human estrogen receptors (12). However,
BPA, like most endocrine-disrupting chemi-
cals, is several orders of magnitude less potent
than 17β-estradiol. Because of the low
expected exposure and the low potency of this
compound, it was assumed that the probability
of reproductive effects was negligible.
However, in utero exposure to low doses of
BPA (between 2 and 50 µg/kg) induced alter-
ations of the reproductive organs such as
increased prostate size (13,14) and decreased
epididymal weight. Similar results were
obtained with low doses of other estrogens,
including diethylstilbestrol (DES). Because
some attempts to replicate these studies have
been unsuccessful (15,16), the issue of low-
dose effects became controversial (17). Several
publications since then have confirmed and
extended the original observations by the vom
Saal group (18). For example, Gupta showed
increased prostate weight, decreased epididy-
mal weight both in vivo and in organ culture,
and enhanced anogenital distance (19). A pos-
sible mechanism through the induction of
androgen receptor was postulated (19,20). In
addition, prenatal exposure in rats altered the
histoarchitecture of the prostate (21).
Females are also affected by perinatal
exposure to BPA. For example, BPA advances
the onset of puberty (22) and alters mammary
gland development in mice (23), and it dis-
rupts estrous cyclicity and decreases LH levels
after long-term ovariectomy in rats (24).
These effects occur at doses several orders of
magnitude below those needed to evoke a
uterotrophic effect (25). Because BPA is not
the sole source of xenoestrogen exposure
in humans, it is likely these chemicals act
additively among themselves and with natural
estrogens (26–28), thus producing effects at
very low doses.
The adverse effects of BPA may not be
limited to the genital tract and mammary
glands. Behavioral disorders were evidenced in
Wistar rat offspring when mothers were
administered BPA during pregnancy and lacta-
tion (29,30); both experiments used doses well
below the no observed adverse effect level of
50 mg/kg/day. In vitro, the mutagenicity of
low concentrations of BPA was demonstrated
using human (31) and Syrian hamster (32)
embryo cells. In addition, it was demonstrated
that BPA could be converted in vitro to
bisphenol o-quinone, a reactive intermediate
able to bind irreversibly to DNA (33).
Understanding the metabolic routes
followed by BPA in mammals is a necessary
step for scientists trying to assess the risk asso-
ciated with the wide use of this chemical.
Indeed, both the pharmacologic and the toxi-
cologic properties of BPA may be modified
when the parental compound is metabolized.
The earliest BPA metabolism study was car-
ried out in 1966 on rats dosed orally with
800 mg/kg BPA (3), showing that BPA
metabolites were mainly excreted via feces, in
which unchanged BPA and its glucuronic
acid (GlcA) conjugate (GlcA-BPA) were the
major compounds identified. Urine was also
an important excretion pathway and appar-
ently contained mainly GlcA-BPA. The same
authors have also hypothesized the formation
of a hydroxylated metabolite of BPA. Most of
these findings have been confirmed by recent
studies in mice and rats. Much of the atten-
tion has been focused on GlcA-BPA, and it is
now accepted that this metabolite is the
major residue of BPA both in vivo (34–36)
and in vitro (37–40), including studies
carried out using human liver microsomes
(39). It has been established that GlcA-BPA
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and 3-hydroxy-BPA have estrogenic potencies
much lower than that of BPA (38,39,41),
and that these metabolites are not expected to
play a role in the reproductive toxicity 
of BPA. More is known about the pharmaco-
kinetics of BPA, mainly in rodents
(9,34,42–44). BPA is quickly absorbed what-
ever the administration route, but its bioavail-
ability is lower when distributed orally
compared with a parenteral administration
(35). Enterohepatic recirculation of BPA
residues has been hypothesized by several
authors (43). The passage of BPA through
the placental barrier and into milk was also
demonstrated (9,36). However, hardly any
data have been published about the nature of
BPA residues in maternal tissues and fetuses,
and its metabolic fate when low doses are
administrated remains to be investigated.
Combining the use of radio–high-perfor-
mance liquid chromatography (HPLC) and
various analytic techniques, we have started an
extensive study of BPA metabolism in preg-
nant CD1 mice. This animal model was cho-
sen because most of the laboratories studying
low-dose effects of BPA and other xenoestro-
gens are using this model (19,23,45,46). In
addition, rodent placentation at late stages of
gestation is histologically close to human pla-
centation, both being of the chorio-allantoid-
ian type with histiotrophic embryo nutrition.
To better understand the fate of this xeno-
estrogen and its possible significance when
administered at a low dosage, we administered
a subcutaneous dose of 25 µg/kg BPA to CD1
mice at day 17 of gestation and sacrificed
them at 0.5, 2, or 24 hr after administration.
We then tried to assess a precise residue quan-
tity, as well as metabolic profiles associated
with BPA residues in tissues, including fetuses.
Additional studies were performed to explore
the fate of BPA when administered orally at
25 µg/kg to CD1 mice and to identify
metabolites. To achieve mass spectral charac-
terization of BPA residues in the pregnant
CD1 mouse, additional animals were dosed
by subcutaneous route at 50 mg/kg.
Materials and Methods
Chemicals
3H-labeled BPA [(3H-BPA); 2,2-bis (4-
hydroxyphenyl)propane] was purchased
from Moravek Biochemicals (Mercury Lane,
Brea, CA, USA) with a specific activity of
185 GBq/mmol. It was stored in ethanol at
–20°C. In these conditions, only limited tri-
tium exchange occurred (< 3%/6 months).
Before the experiments, the solution was
evaporated to dryness under a nitrogen
stream and resuspended in ethanol. Its
purity was greater than 99.9% based on
radio-chromatographic analysis. Unlabeled
BPA (> 99% pure) was purchased from
Sigma Aldrich (L’Isle d’Abeau Chesnes,
France).
Other chemicals, solvents (analytic grade),
and scintillation cocktails were purchased from
the following sources: ammonium acetate,
ammonium carbonate, and sodium citrate,
Sigma Aldrich; methanol and acetonitrile,
Scharlau Chemie S.A. (Barcelona, Spain);
ethanol, citric acid, and acetic acid, Merck
(Briare-Le-Canal, France).
Apparatus
Radioactivity in urine and all other liquid sam-
ples was determined by direct counting on a
Packard scintillation analyzer (Model Tricarb
2200CA; Packard Instruments, Meriden, CT)
using Packard Ultima Gold as the scintillation
cocktail (Packard Instruments, Downer
Grove, IL). Radioactivity in mice carcasses,
tissues, feces, and extraction pellets was deter-
mined by complete combustion using a
Packard Oxidizer 306 (Packard Instruments),
followed by 3H2O quantification on the
Packard scintillation analyzer (scintillation
cocktail: Packard Monophase S and Packard
Permafluor E+, 14:5, v/v). Three replicates
were analyzed for each sample.
Samples were analyzed by HPLC on an
HP1050 apparatus (Hewlett Packard,
Waldbronn, Germany) equipped with a
Rheodyne Model 7125 injector (Rheodyne,
Cotati, CA) connected for radioactivity
detection to a Radiomatic Flo-One/β A500
instrument (Radiomatic, La-Queue-Lez-
Yvelines, France) using Flow-Scint II as the
scintillation cocktail (Packard Instruments)
to establish metabolic profiles, or to an HP
1050 UV detector set at 270 nm and a
Gilson Model 201/202 fraction collector
(Gilson France, Villiers-Le-Bel, France) for
metabolite purification.
Mass spectrometric experiments were
performed using a Finnigan LCQ ion trap
spectrometer (Thermo Finnigan, Les Ullis,
France) equipped with an electrospray ion-
ization (ESI) source. Typical conditions for
recording mass spectra were as follows: spray
voltage, 4 kV; capillary voltage, –22V; capil-
lary temperature, 200°C. All mass spectra
were acquired using automatic gain control
conditions and the helium buffer gas was
used as collision gas for mass spectrometry
(MS)n studies. Sample solutions [5–10
ng/µL in methanol/water (1:1, v/v)] were
infused at a flow rate of 3 µL/min into the
ionization source.
1H and two-dimensional nuclear magnetic
resonance (2D-NMR) spectra were acquired
on a Bruker Avance DMX 500 spectrometer
(Bruker, Wissembourg, France) in CD3OD
solution [50 µg sample/100 µL solvent in a
2.5 tube (outer diameter)]. All measurements
were obtained using a Bruker cryoprobe TXI
at 30°C with trimethylsylane as standard.
All samples were stored and processed in
single-use glass flasks or clean glassware, except
where otherwise indicated.
Animals
Metabolic fate of bisphenol A in pregnant
CD1 mice after subcutaneous administration.
After a 6-day adaptation period with free
access to water and a standard diet (UAR 210;
UAR, Villemoisson-Sur-Orge, France) under a
12-hr light/dark cycle, 11 pregnant CD1 mice
purchased from Harlan (Gannat, France) were
individually housed in stainless steel metabolic
cages at day 17 of gestation with free access to
water. Animals were weighed and randomly
divided into four lots (I, II, III: n = 3; IV:
n = 2). Calculated mean mice weight was not
significantly different between lots.
Lots I, II, and III (metabolic balance).
Animals were individually injected with
25 µg/kg 3H-BPA dissolved in peanut oil and
adjusted with unlabeled BPA to obtain a final
specific activity of 572.2 kBq/µg (lots I, II) or
811.3 kBq/µg (lot III). For each animal, the
radioactivity remaining in the syringe and
needle used for subcutaneous injection was
measured to calculate the quantity of BPA
really administered. After 0.5, 2, and 24 hr,
respectively, mice from lots I, II, and III were
anesthetized with ether and exsanguinated.
Blood, liver, peritoneal fat, gall bladder,
uterus, and ovaries were collected, as well as
the digestive tract, including its content (from
duodenum to rectum), and the remaining car-
cass. Uteri were individually processed to sep-
arate fetuses, placenta, amniotic fluid, and the
uterus itself. For lot III (24-hr experiment)
urine and feces were also collected and meta-
bolic cages were washed with 100 mL ethanol
from which aliquots were taken for residual
radioactivity determination. All samples were
stored at –20°C if not used immediately.
Lot IV (metabolite production for
structural characterization). Animals were
individually injected with 50 mg/kg of a 3H-
BPA solution adjusted with unlabeled BPA
to 301.6 Bq/µg and dissolved in peanut oil.
Mice were sacrificed as described above 24
hr after BPA dosage. Similar tissue samples
were collected, as well as urine and feces.
Bisphenol A metabolism in CD1 mice
after oral administration. Three adult non-
pregnant female CD1 mice (lot V) were
obtained from Harlan, handled in the same
conditions as indicated above, and force-fed
a single oral dose of 25 µg/kg of a 3H-BPA
solution adjusted with unlabeled BPA to
572.2 kBq/µg dissolved in peanut oil. Urine
and feces were collected over a 24-hr period,
after which animals were sacrificed as
described above. Blood, liver, ovaries,
uterus, and carcasses were collected for
radioactivity quantification. Radioactivity
remaining in the material used for injection
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was determined to allow actual BPA dosage
calculation.
Analytic Procedure
Metabolite profiling. HPLC coupled to on-
line radioactivity detection was used for
metabolite profiling. The HPLC system con-
sisted of a Zorbax C18 column (250 × 4.6
mm, 5 µm) (Interchim, Montluçon, France)
coupled to a Kromasil C18 guard precolumn
(18 × 4.6 mm, 5 µm) (Interchim). Mobile
phases consisted of ammonium acetate buffer
(20 mM, pH 3.5) and acetonitrile 95:5 v/v
in A and 10:90 v/v in B, respectively. Flow
rate was 1 mL/min at 35°C. A three-step gra-
dient was used as follows: 0–4 min 100% A;
4–6 min linear gradient from 100% A to A:B
85:15 v/v; 6–16 min A:B 85:15 v/v; 16–18
min linear gradient from 15% B to 25% B;
18–28 min A:B 75:25 v/v; 28–30 min linear
gradient leading to 100% B; 30–40 min
100% B.
Sample processing. Urine samples were
mixed with methanol (1:2, v/v), stirred and
centrifuged for 10 min at 6,000 × g and 4°C.
The pellet was discarded. The supernatant
was concentrated under a nitrogen stream
before radio-HPLC analysis.
Liver, fetuses, and placenta. For each
mouse, liver, pooled placenta, and three fetuses
were separately homogenized and the radioac-
tivity present in these samples was determined
after combustion. The remaining samples,
including the rest of fetuses (pools of three to
five, depending on litter size) were processed
following an identical procedure: Approx-
imately 5 g of tissue was homogenized with
5 mL/g acetonitrile/methanol/ammonium
acetate buffer 40 mM, pH 3.2 (6:3:1, v/v/v),
using a Polytron homogenizer (Kinematica,
Lucerne, Switzerland), then centrifuged at
8,000 × g and 4°C for 10 min. The radioactiv-
ity extracted was determined, the supernatant
was stored at –20°C, and the pellet was sub-
jected to five additional extractions: twice with
the same mixture, then three times using 5
mL/g acetonitrile/methanol/ammonium car-
bonate buffer 40 mM, pH 8 (6:3:1, v/v/v).
Residual radioactivity remaining in the last
centrifugation pellet (nonextractable radioac-
tivity) was determined after combustion in an
oxidizer. The first two acidic extracts were
pooled, delipidated using acetonitrile-saturated
isooctane, concentrated under vacuum, and fil-
tered through 45-µm nylon Acrodisc filtering
units (Gelman, Ann Arbor, MI, USA) before
radio-HPLC analysis.
Feces and digestive tracts (including their
contents) were extracted successively six
times using the procedure described above,
except ethanol (5 mL/g) was used instead of
the acidic and basic solvent mixtures. After
radioactivity determination, ethanol was
added to bile samples (9:1 v/v), that were
stirred, centrifuged (10 min, 5,000 × g, 4°C),
concentrated, and analyzed by radio-HPLC.
Plasma and amniotic fluid. Blood was
collected in heparinized tubes and immedi-
ately centrifuged at 1,500 × g (10 min, 4°C).
Radioactivity in red blood cell pellets was
determined by combustion in an oxidizer.
Radioactivity in plasmas and amniotic fluids
was determined by direct counting of
aliquots. The remaining material was then
extracted and analyzed using the same
method as described for bile.
Volatile radioactivity quantification. After
extraction, aliquots (typically 20, 40, and
80 µL) were taken for radioactivity determina-
tion. Identical aliquots were evaporated to dry-
ness and rediluted in 100 µL ethanol before
radioactivity determination. For each sample
tested (placenta, amniotic fluid, plasma, and
fetuses), this procedure was carried out in trip-
licate, thus allowing the calculation of the
mean percentage of volatile radioactivity.
Metabolite isolation. BPA metabolites
were isolated from urine, digestive tract, liver,
feces, and fetus samples from lot IV mice.
Using the extraction procedure described
above, samples were concentrated under a
nitrogen stream, rediluted in 10 mL ammo-
nium acetate buffer 50 mM adjusted to pH
3.2, and extracted using an Oasis HLB 0.5 g
LP cartridge (Waters, Milford, MA, USA)
previously washed with methanol (10 mL)
and equilibrated with the buffer (10 mL).
Elution was performed successively with
10 mL of the ammonium acetate buffer and
then three times with methanol (10 mL).
Methanol fractions containing radioactivity
(usually only the first one) were concentrated
under a nitrogen stream before HPLC separa-
tion using the same apparatus as described for
the analytic system, but with mobile phases
consisting of an acetic acid solution (pH 2.8)
and acetonitrile (95:5 and 10:90 v/v in A and
B, respectively). Flow rate was 1 mL/min at
35°C. Gradient was as follows: 0–4 min
100% A; 4–39 min linear gradient from
100% A to 100% B; 39–44 min 100% B.
Enzymatic tests. With the methods
described above, 600 Bq metabolite F was iso-
lated from fetus extracts (lots I–III). The
metabolite was diluted in sodium citrate buffer
0.1 M and its purity was verified by radio-
chromatography. Assay 1: 10 µL (0.1 unit)
Aspergillus niger N-acetyl glucosaminidase
(Sigma) was added to 150 Bq metabolite F in
300 µL buffer adjusted to pH 4. Assay 2:
10 µL (0.1 unit) chicken liver N-acetyl galac-
tosaminidase (Sigma) was added to 150 Bq
metabolite F in 300 µL buffer adjusted to pH
3.65. Both incubations were carried out at
37°C for 2 hr. Radio-chromatographic analy-
ses of the incubation media were achieved by
spiking separately approximately 50 Bq of the
incubates, fortified or not with 50 Bq of the
original metabolite. Controls were carried out
using similar conditions with no enzyme.
Metabolite identification. For each sample,
a 10 ng/µL solution in CH3OH/H2O (1:1
v/v) was introduced into the ion source at a
flow rate of 3 µL/min. All isolated metabolites
were analyzed by MS using negative ESI
mode. When necessary, additional analyses
were performed using negative ionization
mode. MSn experiments were carried out on
the metabolite’s quasi-molecular ions, allowing
the determination of their structure.
For some metabolites, hydrogen/deu-
terium (H/D) exchange experiments were
performed using CH3OD/D2O as the solvent
to provide further structural information.
Under such conditions, all mobile hydrogen
atoms were exchanged with deuterium atoms,
resulting in a shift in the m/z ratio of the
studied ion.
Statistical analysis. Comparison between
values was achieved using the Student t-test.
Results
BPA Distribution and Residual Levels
The radioactivity remaining in the material
used to dose the animals was measured. For
mice given a 25 µg/kg nominal dosage, cor-
rected values were 20.9 ± 1.4 µg/kg (lot I),
21.3 ± 1.3 µg/kg (lot II), 22.1 ± 1.4 µg/kg
(lot III), and 22.4 ± 1.3 µg/kg (lot V), with
no significant difference between groups;
mice given 50 mg/kg (lot IV) received an
actual dosage of 46.1 ± 2.1 mg/kg BPA.
Twenty-four-hour metabolic balance in
pregnant mice dosed subcutaneously with 25
µg/kg BPA (lot III). Residual levels of
radioactivity measured in excreta and tissues
are summarized in Table 1, with the corre-
sponding concentrations expressed in
nanograms per gram ± SD of BPA equiva-
lent. Total recovery for this experiment was
85.7 ± 6.4% of the administered radioactiv-
ity. Urine contained less than 6% of the
administered radioactivity. The digestive
tract (including its contents) contained most
of the administered dose (45%); feces con-
tained 21%. Gall bladders contained less
than 2% of the administered radioactivity,
though for all three mice they were filled
with bile. The highest residual levels were
found in liver (12 ng/g); it contained about
2.5% of the administered radioactivity.
Residual levels calculated for whole blood
corresponded to 2.2 ± 0.3 ng/mL, about
85% of these residues being associated with
the plasma fraction. In the reproductive
tract, residual levels ranged from 2.2 to
4.8 ng/g, respectively, for ovaries and amni-
otic fluids, whereas fetuses (3.7 ng/g)
accounted for a total of 4% of the adminis-
tered radioactivity, regardless of litter size
(9, 13, and 16 fetuses for the three mice).
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Comparative study at 0.5, 2, and 24 hr in
pregnant mice dosed subcutaneously with
25 µg/kg BPA (lots I, II, III). Radioactivity
levels recovered from maternal plasma and
liver, placenta, amniotic fluid, and fetuses are
summarized in Figure 1, as well as the propor-
tion of the nonextractable, extractable volatile,
and extractable nonvolatile (later analyzed by
radio-HPLC) radioactivity fractions, respec-
tively. Residual levels are also given for uterus
and ovaries, but no extraction was carried out
on these low-weight samples.
With the exception of plasma, the highest
levels of radioactivity were detected 30 min
after BPA administration (lot I). For these
mice, the highest concentrations of residues
were found in liver, uterus, and placenta
(20–40 ng/g), whereas in ovaries, amniotic
fluid, and fetuses, levels were in the 10 ng/g
range. Because of the large SDs observed in lot
I, differences among the three time points were
not statistically significant, except for liver
(p < 0.01) and ovaries (p < 0.05). As shown
in Figure 1, the amount of nonextractable
residues was low at 2 or 24 hr after BPA
dosage and was slightly higher at 0.5 hr. The
main difference between the 2- and 24-hr
points was a higher proportion of volatile
radioactivity for the latter lot, representing
more than two-thirds of the residues extracted
from amniotic fluid, fetuses, and maternal
plasma after 24 hr. In liver, relatively high lev-
els of radioactivity were found in extraction
pellets, and the proportion of volatile radio-
activity remained low even at 24 hr.
Residual levels in pregnant CD1 mice
dosed subcutaneously with 50 mg/kg BPA
(lot IV). Two animals were used to produce
enough material for BPA metabolite isolation
and to check a possible change in BPA meta-
bolic routes. Thus, no attempt has been made
to compare this lot with the other ones. The
mean BPA residual levels measured in liver,
ovaries, uterus, amniotic fluid, and fetuses
were 14, 1.7, 9.4, 6.4, and 4.3 µg/g, respec-
tively. Radioactivity distribution was compa-
rable to that observed in mice dosed with
25 µg/kg BPA.
Residual levels in CD1 mice dosed orally
with 25 µg/kg BPA (lot V). For this lot,
residual radioactivity levels measured in
blood, ovaries, and uterus (27 ± 9, 21 ± 5,
and 160 ± 70 pg/g, respectively) were
significantly lower than those obtained for
lot III mice (p < 0.0001), whereas for liver
(6.3 ± 2.4 ppb), the difference was not sta-
tistically significant. In contrast, more
residues were detected in mouse carcasses
after oral dosage (8.0 ± 0.6 ng/g, p < 0.001).
When submitted to radio-HPLC analysis,
urinary and fecal extracts revealed no quali-
tative difference when compared with lot III
mice samples (data not shown).
Qualitative Study of BPA Excretion
The structures of the main BPA metabolites
identified in this work are summarized in
Table 2, together with their corresponding
codes and mass spectral characteristics.
Urinary excretion. The HPLC conditions
developed for this study allowed the separation
of 10 different radioactive peaks from urine
samples. After analysis of all urine samples, no
major difference was observed between lots I,
II, and III mice (25 µg/kg, subcutaneous
dosage), lot IV mice (50 mg/kg), and lot V
mice (oral dosage). A representative analysis is
shown in Figure 2. Unchanged BPA [retention
time (Rt), 33.5 min] was detected in very low
quantities in urine, whereas two major
metabolites (GlcA-BPA-OH and GlcA-BPA)
accounted for more than two-thirds of the
radioactivity.
Fecal excretion. Results obtained after the
analysis of feces, bile, and digestive tracts are
summarized in Table 3 for lot III mice. Fecal
radioactivity was mostly associated with
unchanged BPA (> 95%), whereas biliary
extracts consisted of more than 90% GlcA-
BPA. Surprisingly, digestive tract extracts were
found to contain, in addition to these two
compounds, a third major metabolite of inter-
mediary polarity, later identified as GlcA DH-
BPA. A representative radio-chromatogram for
pregnant CD1 mice is presented in Figure 3,
showing the presence of additional metabolites
exhibiting similar Rts to compounds already
detected in urine. Again, no major qualitative
differences were observed for lots IV and V.
Metabolite identification. All structural
characterizations have been achieved on
material isolated from lot IV mice, using neg-
ative ionization ESI/MSn. Additional details
and mass spectral data are summarized in
Table 2. The structure of unchanged BPA
(Rt, 33.5 min) was confirmed for all analyzed
tissues where it was detected.
GlcA-BPA, with an Rt of 25 min, was the
major metabolite in urine and digestive tract
extracts. It was directly characterized from both
matrices as well as from liver extracts. [M–H]–
ion was detected at m/z 403. In MS2 experi-
ments, fragmentation of this quasi-molecular
ion led to the pair of complementary frag-
ment ions at m/z 277 (corresponding to
deprotonated BPA) and m/z 175, characteristic
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Table 1. Twenty-four-hour metabolic balance of BPA in pregnant CD1 mice dosed subcutaneously with
25 µg/kg BPA at day 17 of gestation (mean of three animals ± SD).
Percent of administered ng/g or ng/mL
radioactivity (3H-BPA equivalents)
Blood 0.17 ± 0.06 2.20 ± 0.29
Ovaries 0.01 ± 0.00 2.25 ± 0.26
Uterus 0.40 ± 0.01 3.45 ± 0.13
Placenta 0.55 ± 0.02 3.14 ± 0.34
Amniotic fluid 0.34 ± 0.17 4.85 ± 0.47
Fetus (n = 3) 0.33 ± 0.06 3.70 ± 0.38
Fetus (littera) 4.13 ± 0.46
Liver 2.48 ± 0.83 11.95 ± 4.12
Bile 1.87 ± 0.35 1.66 ± 0.32
Digestive tractb 45.30 ± 0.38
Feces 21.23 ± 6.70
Urine 5.72 ± 1.33 8.16 ± 1.82
Fat 0.01 ± 0.01 0.75 ± 0.22
Carcass 2.75 ± 1.17 1.37 ± 0.58
Cages 0.72 ± 0.34
Total 85.68 ± 6.42
aTotal radioactivity recovered for the whole litter. bTotal radioactivity recovered from duodenum to rectum, including the
digestive tract content.
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Figure 1. Residual levels of radioactivity measured 0.5, 2, and 24 hr after a subcutaneous injection of
25 µg/kg 3H-BPA to CD1 mice at day 17 of gestation, in (A) plasma, placenta, amniotic fluid, and fetus and
(B) liver, uterus, ovaries, and carcass. Results (mean ± SD, n = 3) are expressed in nanograms per gram
BPA equivalent.
of a glucuronide moiety. The loss of water was
also observed (m/z 385), probably originating
from the glucuronide moiety, because further
dissociation of the m/z 385 ion in a subsequent
MS3 experiment led to the formation of an
m/z 227 ion (deprotonated BPA). Thus, this
metabolite was identified as the GlcA conju-
gate of BPA.
GlcA DH-BPA represented about 30% of
the radioactivity detected in digestive tracts
(lot III), thus accounting for more than 15%
of the BPA residues formed in vivo. It was iso-
lated from this matrix. [M–H]– quasi-molecu-
lar ion was detected at m/z 385, and the MS2
spectrum of this ion was identical to that of
the m/z 385 fragment ion produced by water
loss from the m/z 403 deprotonated ion of
GlcA-BPA. These data indicated that GlcA
DH-BPA may be a dehydrated form of the
GlcA conjugate of BPA.
Additional support for this hypothesis was
provided by H/D exchange experiments using
CH3OD/D2O as the solvent for ESI experi-
ments. In these conditions, the quasi-molecular
ion of GlcA-BPA was shifted from m/z 403 to
m/z 407, consistent with the presence of five
exchangeable hydrogen atoms in GlcA-BPA,
whereas the quasi-molecular ion of GlcA DH-
BPA was shifted from m/z 385 to m/z 388,
indicating the presence of four exchangeable
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Figure 2. Typical radio-chromatographic profile for
0- to 24-hr urine collected from mice dosed subcuta-
neously with 25 µg/kg 3H-BPA at day 17 of gestation.
Abbreviations: NI, unidentified metabolite; F, Rt cor-
responding to metabolite F; all other structures are
detailed in Table 2.
Table 2. Rt, code, structure, and mass spectral data for most of the BPA metabolites identified in this study.
Rt Metabolite code Quasi-molecular ion Observed fragment
(min) (identified from) Metabolite structure [M–H]– (m/z) ions in ESI-MSn (m/z)
11.5 GlcA-BPA-OH 419 (a) 243 (MS2 419)
(urine) (b) 175 (MS2 419)
(c) 213 (MS3 419, MS2 243)
17.5 GlcA-BPA-Glc 565 (a) 175 (MS2 565)
(urine) (b) 403 (MS2 565)
(a) 175 (MS3 565-403)
22a HO3S-BPA-GlcA DH 481 (a) 401 (MS2 481)
| (b) 243 (MS3 481-401)
OH
(digestive tract)
22b HO3S-BPA-GlcA DH 495 (a) 415 (MS2 495)
| (b) 257 (MS3 495-415)
OCH3 (c) 242 (MS4 495-415-257)
(digestive tract)
22c HO3S-BPA-Glc 499 (a) 337 (MS2 499)
| (b) 257 (MS3 499-337)
OCH3 (c) 242 (MS4 499-337-257)
(liver, urine) (d) 227 (MS5 499-337-257-242)
(e) 109 (MS6 499-337-257-242-227)
OH (a) 353 (MS2 515)
| (b) 273 (MS3 515-353)
22d HO3S-BPA-Glc 515 (c) 258 (MS4 515-353-273)
| (d) 243 (MS5 515-353-273-258)
OCH3 (e) 228 (MS6 515-353-273-258-243)
(liver, urine) (f) 109 (MS6 515-353-273-258-243)
25 GlcA-BPA 403 (a) 227 (MS2 403)
(urine, liver, (b) 175 (MS2 403)
digestive tract)
29 GlcA DH-BPA 385 (a) 227 (MS2 385)
(digestive tract) (b) 157 (MS2 385)
31.5 HO3S-BPA 307 (a) 227 (MS2 307)
(feces, urine)
32.5 HO-BPA 243 (a) 228 (MS2 243)
(feces) (b) 149 (MS2 243)
(c) 93 (MS2 243)
(d) 109 MS2 243)
GlcA DH, dehydrated glucuronide. Metabolites have been isolated from urine, liver, or the digestive tract, as indicated. Because the exact position of conjugation and/or hydroxylations
cannot be unambiguously determined by ESI-MS analysis, a different configuration cannot be ruled out for metabolites 22a–22d.
hydrogen atoms in this species (Figure 4). For
the latter compound, the MS2 spectrum of the
quasi-molecular [Md4–D]– ion at m/z 388 dis-
played characteristic fragment ions at m/z 344
(CO2 elimination from the glucuronide moi-
ety), and a pair of complementary fragment
ions at m/z 228 and m/z 158, corresponding to
the BPA and the glucuronide moieties, respec-
tively. The m/z 158 (instead of m/z 157 under
nonlabeling conditions) product ion evidenced
the occurrence of only one exchangeable
hydrogen atom on this fragment ion. Given
this information, only one possible position of
the double bond in the GlcA moiety allows the
formation of a monodeuterated fragment ion
at m/z 158, according to the decomposition
scheme proposed in Figure 4.
To confirm this hypothesis, this metabolite
was investigated using 1H and 2D-NMR,
including gradient selection (gs)-correlation
spectroscopy, gs-heteronuclear multiple quan-
tum coherence (HMQC), and gs-heteronu-
clear multiple bonding coherence (HMBC).
The 1H NMR spectrum recorded in CD3OD
displayed characteristic signals (Table 4).
Beside aromatic signals of BPA (two AB spin
systems), of particular importance is the
observation of resonances in the sugar region:
a triplet for H2´, two doublets for H1´
and H4´, and a double doublet for H3´.
Then the structure of GlcA DH-BPA was
unambiguously established using 2D-NMR
techniques. Moreover, 13C chemical shifts
were determined from the F1 projection of
HMQC and HMBC diagrams, because the
weak amount of metabolite (50 µg) precluded
the direct measurement of a carbon spectrum.
These results were in agreement with the struc-
ture proposed by MS, double-bond resonances
being observed for the metabolite. It is worth
noting that the signal of carboxylic acid C6´
carbon was not observed, as is frequently the
case for glucuronides. Furthermore, long-range
correlations in the HMBC spectrum allowed
us to rule out any other position for the double
bond on the dehydrated form of GlcA.
Thus, the results obtained support the
structural characterization of a dehydrated
glucuronide conjugate of BPA.
GlcA-BPA-OH, the second major urinary
metabolite (Rt, 11.5 min) was isolated from
urine. This metabolite exhibited an [M–H]–
ion at m/z 419. The fragmentation of this ion
(MS2) led to the formation of the m/z 175
(GlcA moiety) and m/z 243 fragment ions,
the latter likely corresponding to hydroxy-
lated BPA. To get more structural informa-
tion, the m/z 243 fragment ion was submitted
to collisional excitation in a subsequent MS3
experiment. The corresponding mass spec-
trum displayed characteristic fragment ions
at m/z 225 (loss of H2O) and m/z 213 (loss
of CH2O), allowing us to locate the hydrox-
ylation site on one of the two methyl groups
of BPA.
GlcA-BPA-glucose (Glc), with an Rt of
17.5 min, was isolated from urine. The
[M–H]– quasi-molecular ion was detected at
m/z 565. The MS2 spectrum of this m/z 565
ion showed fragment ions due to the appar-
ent loss of Glc (m/z 403) as well as a GlcA
moiety (m/z 175). Moreover, MS3 spectrum
of the m/z 403 ion was identical to that of the
m/z 403 [M–H]– molecular ion of GlcA-
BPA. Thus, this metabolite should be consid-
ered a GlcA/Glc double conjugate of BPA, as
indicated in Table 2.
At least two polar metabolites were
detected in urine samples, between the Rt of
GlcA-BPA-OH and GlcA-BPA-Glc. These
compounds have not been identif ied.
Metabolite F (Rt, 24 min) was detected in
low amounts in urine and digestive tract
extracts. Its structural characterization was
achieved only from liver and fetuses and is
detailed elsewhere.
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Figure 4. Proposed decomposition pathway of the m/z 388 [Md4–D]– ion of GlcA DH-BPA submitted to MS/MS.
Table 3. Metabolite distribution in bile, digestive tract, and feces of mice dosed subcutaneously with 25 µg/kg 3H-BPA at day 17 of gestation.
HO3S-BPA
Metabolite GlcA-BPA-OH 22a/22b F GlcA-BPA GlcA DH-BPA HO-BPA BPA NI
Rt (min) 11.5 22 23.7 25 29 31.5–32.5 33.5
Bile 3.0 ± 1.5 0.8 ± 0.8 92 ± 3.6 2.3 ± 2.0 1.4 ± 1.2
Digestive tract 3.0 ± 1.4 2.0 ± 1.5 1.0 ± 0.9 38 ± 12 29.4 ± 14.4 0.2 ± 0.3 23 ± 7.0 2.8 ± 1.9
Feces 0.9 ± 0.2 1.0 ± 1.3 96 ± 1.2 3.3 ± 1.7
Abbreviations: NI, unidentified metabolites; F, Rt corresponding to metabolite F; all other structures are detailed in Table 2. Results are presented as mean percentage ± SD (n = 3 animals)
on the basis of sample extracts analyses carried out 24 hr after BPA dosage. 
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Figure 3. Typical radio-chromatographic profile for
0- to 24-hr feces collected from mice dosed sub-
cutaneously with 25 µg/kg 3H-BPA at day 17 of
gestation. Abbreviations: NI, unidentified metabo-
lite; F, Rt corresponding to metabolite F; all other
structures are detailed in Table 2.
MS analysis of the radioactive peak of
metabolites 22a, 22b, 22c, and 22d with an Rt
of 22 min led to different results, depending
on the extracted matrix.
When isolated from the digestive tract, this
peak included two different structures. For the
first one, the [M–H]– ion was detected at m/z
481. Under resonant excitation conditions,
this m/z 481 ion decomposed into the m/z 401
ion by SO3 elimination from a sulfate group.
The MS3 spectrum of the m/z 401 ion result-
ing from the decomposition of the m/z 481
ion showed a fragment ion at m/z 243, corre-
sponding to hydroxylated BPA. No water loss
was observed for the m/z 401 ion, suggesting
that the hydroxylation took place on the aro-
matic cycle rather than on one of the methyl
groups of BPA. In the same way observed for
GlcA DH-BPA, the formation of the m/z 243
ion from the selected m/z 401 parent ion
should correspond to the elimination of a neu-
tral dehydrated glucuronide moiety. Therefore,
metabolite 22a was tentatively identified as a
double conjugate (sulfate/dehydrated glu-
curonide) of hydroxylated BPA, as indicated in
Table 2. The second compound evidenced
from the mass spectrum presented a [M–H]–
quasi-molecular ion at m/z 495, indicating the
presence of an additional methyl group, when
compared with 22a. Moreover, its fragmenta-
tion pathway was similar to that of 22a, i.e.,
loss of sulfate (m/z 415, MS2) and loss of a
dehydrated glucuronide (m/z 257, MS3). The
latter ion dissociation evidenced an additional
methyl loss (m/z 242, MS4). Thus, metabolite
22b should correspond to the double conju-
gate (sulfate/dehydrated glucuronide) of
methoxylated BPA.
When isolated from urine, again, two
metabolites could be evidenced from the full
spectrum of the Rt 22 min peak, but the
structures evidenced were not metabolites
22a and 22b. Both 22c and 22d showed a
close fragmentation pattern, the respective
[M-H]– ions being detected at m/z 499
(22c) and m/z 515 (22d). MS2 and MS3
analyses (see Table 2) demonstrated that
both were double conjugates (sulfate/Glc).
MS4 and MS5 fragmentation indicated the
successive loss of two methyl groups.
Moreover, the MS6 spectra from both m/z
499 and m/z 515 showed an m/z 109 frag-
ment ion characteristic of a doubly hydroxy-
lated aromatic cycle. For the m/z 515 ion, a
third methyl group loss was also observed
(m/z 228). Thus, it is hypothesized that 22c
is a Glc/sulfate double conjugate of
methoxylated BPA and 22d, the same struc-
ture bearing an additional hydroxy group.
HO3S-BPA, with an Rt of 31.5 min, was
identified from both urine and feces. This
metabolite gave a [M–H]– quasi-molecular
ion at m/z 243. Decomposition of this ion (in
MS2 experiment) led to a fragment ion at m/z
227 corresponding to deprotonated BPA,
indicating a loss of SO3 from a sulfate group.
This allowed us to consider this metabolite as
a sulfate conjugate of BPA.
HO-BPA was identified from fecal
extracts. Because it was detected in very low
amounts and was not perfectly separated
from HO3S-BPA by HPLC, we choose to
quantify both metabolites together (see
Table 3). The mass spectrometric analysis of
this metabolite showed an ion at m/z 243.
This m/z value was consistent with that of
the [M–H]– deprotonated ion of hydroxy-
lated BPA. This was confirmed by the MS2
spectrum, showing decomposition into a
fragment ion at m/z 228 by loss of a methyl
group. The presence of low abundant frag-
ments at m/z 149 and particularly at m/z
109 were diagnostic of aromatic hydroxyla-
tion (Table 2). Hence, these results suggest
that this metabolite arises from an aromatic
hydroxylation of BPA. We cannot rule out
the possibility that HO-BPA would also be
excreted in urine, although it has not been
characterized directly from this matrix.
BPA Metabolite Study in Maternal
Tissues and Fetuses
Metabolic profiles. Radio-chromatographic
profiles were obtained individually for all lot I,
II, and III mice amniotic fluids, placentas,
plasmas, livers, and fetuses (pool of three).
They were qualitatively similar for these dif-
ferent biologic matrices, though quantitative
differences were observed. Moreover, they
were also similar for lot IV mice, which have
been used for metabolite isolation. A represen-
tative fetal extract analysis is shown in Figure
5. Unchanged BPA, GlcA-BPA, and metabo-
lite F were the major compounds detected in
all these tissues. Minor metabolites were also
detected, and could correspond, on the basis
of their Rt, to structures already identified
from urine and digestive tracts extracts: GlcA-
BPA-OH and GlcA-BPA-Glc, as well as
HO3S-BPA (and/or HO-BPA), GlcA DH-
BPA, and trace amounts of metabolites eluted
with an Rt of 22 min (only for liver extracts).
Metabolite quantification. Because we had
established that the proportion of nonex-
tractable radioactivity and extractable volatile
radioactivity varied for lots I, II, and III
(Figure 1), actual concentrations of the major
metabolites present in the reproductive tract,
liver, and fetuses were calculated in
nanograms per gram, on the basis of the
amount of nonvolatile extractable radioactiv-
ity present in these tissues and analyzed by
radio-HPLC. Results are presented in Table 5.
The major compound in all samples was
GlcA-BPA, except the placenta, where
unchanged BPA and metabolite F represented
more than 70% (at 0.5 hr) and about 60% (at
24 hr), respectively, of the analyzed radioactiv-
ity, according to their HPLC Rts. BPA con-
centration decreased quickly, as well as that of
most minor metabolites. However, except for
plasma, the proportion of metabolite F
increased with time, and its concentration rose
in placentas and amniotic fluids. In maternal
livers, the proportion of the three major
metabolites was relatively stable between 0.5
and 24 hr.
Metabolite identification. The structures of
BPA and GlcA-BPA were confirmed after the
isolation of metabolites from both liver and
fetuses. For liver, the radioactive peak with an
Rt of 22 min was also isolated, and when sub-
mitted to ESI-MS, this sample produced
results similar to those established for the same
Rt peak obtained from urine, evidencing
metabolites 22c and 22d.
The structure of metabolite F, purified
from fetus extracts, was studied by ESI/MS in
both negative and positive ionization modes
(Figure 6). Its MS analysis produced identical
results when F was isolated from liver extracts.
The negative ESI analysis of F gave an
[M– H]– ion at m/z 606, indicating an odd
molecular weight (607) and thus the presence
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Table 4. 13C and 1H chemical shifts of GlcA DH-
BPAa,b (atom numbering according to Figure 4).
Atom δ 13Cc δ 1H
1 155.90 —
2 117.06 7.08 (d) J = 8.9 Hz
3 128.12 7.13 (d) J = 8.9 Hz
4 146.13 —
5 42.11 —
6 142.54 —
7 128.07 7.01 (d) J = 8.7 Hz
8 114.93 6.65 (d) J = 8.7 Hz
9 155.39 —
10 30.95 1.59 (s)
1´ 100.29 5.46 (d) J = 5.8 Hz
2´ 71.72 3.84 (t) J = 5.5 Hz
3´ 68.28 4.16 (dd) J = 5.0, 4.0 Hz
4´ 108.29 5.90 (d) J = 3.5 Hz
5´ 145.83 —
6´d NOd —
aIn ppm from trimethylsylane; solvent: CD3OD. bAssignments
obtained from 2D measurements. cDetermined from the
cross sections of HMBC and HMQC diagrams. dSignal not
observed.
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Figure 5. Typical radio-chromatographic profile
obtained for fetus extracts after mice subcuta-
neous dosage with 25 µg/g 3H-BPA. The displayed
chromatogram was obtained 2 hr after BPA dosage
(lot II).
of an odd number of nitrogen atoms (Figure
6A). MS2 experiments carried out on this ion
evidenced the formation of an m/z 385 ion,
and thus the loss of 221 mass units. Further
fragmentation of the m/z 385 ion was similar
to that of GlcA DH-BPA.
Under positive ESI conditions, quasi-
molecular [M+H]+ and [M+Na]+ species were
detected at m/z 608 and 630, respectively
(Figure 6B). The MS2 spectrum of the
[M+H]+ ion exhibited an m/z 204 ion, with
the loss of 404 mass units corresponding to a
glucuronide conjugate of BPA. Thus, F could
not be a metabolite in which BPA was conju-
gated to a dehydrated glucuronide. An m/z
380 ion fragment (formed by the loss of
BPA) was also observed in MS2, suggesting
that the m/z 204 ion arose from a moiety
directly linked to the glucuronide. Further
dissociation of the m/z 204 ion led to m/z 186
(loss of a molecule of water, MS3), which
itself gave m/z 168 (loss of a molecule of
water) and m/z 144 (loss of CH2CO) when
submitted to MS4 analysis, indicating the
presence of an acetyl group.
All data from these two complementary
analyses were consistent with a structure where
BPA glucuronide was linked to an acetylated
galactosamine (or glucosamine). Thus it was
hypothesized that metabolite F was a GlcA
conjugate of BPA, the GlcA itself being conju-
gated to N-acetyl-galactosamine (or N-acetyl
glucosamine). Though the eventuality that
these conjugations would take place on the
two phenols of BPA cannot totally be ruled
out, our MS data, with the observation of an
[M+H]+ m/z 380 ion (corresponding to the
disaccharide moiety), indicate that N-acetyl
galactosamine should be linked directly to one
of the hydroxyl groups of the GlcA. Because it
was impossible to submit metabolite F to
NMR analysis because of the low quantities
available, we purified this compound from
remaining lots I, II, and III fetuses and con-
duced enzymatic experiments on the com-
pound using either N-acetyl glucosaminidase
or N-acetyl galactosaminidase. In the first case,
metabolite F was left unchanged after the incu-
bation, whereas the second enzyme produced a
100% radio-HPLC shift of F (Rt, 24 min) to
the Rt of GlcA-BPA (25 min). This Rt shift
was confirmed by the radio-HPLC analysis of
a known amount of metabolite F for which
50% had been incubated with N-acetyl galac-
tosaminidase and 50% was not, demonstrating
that F and GlcA-BPA were perfectly separated
(Figure 7). Thus, it was concluded metabolite
F was a double conjugate of BPA to GlcA and
N-acetyl galactosamine, for which a possible
structure is displayed in Figure 8.
Discussion
The present study was carried out in pregnant
CD1 mice at a late stage of gestation with a
nominal dosage of 25 µg/kg BPA, corre-
sponding to an actual dosage of 20–23 µg/kg.
The goal was to investigate the metabolic fate
of BPA in an animal model in which this
chemical alters the genital tract and mam-
mary gland when administered at low doses
during gestation (13,14,18,19,22,23,45).
The core study focused on the development
of analytic methods allowing us to character-
ize the structure of BPA metabolites both in
maternal tissues and fetuses, 0.5, 2, and 24 hr
after BPA was injected by subcutaneous
route. Additional information was acquired
from pregnant mice dosed subcutaneously
with 50 mg/kg BPA and nonpregnant mice
dosed orally with 25 µg/kg BPA, allowing
some comparisons with previously reported
pharmacokinetic data (9,35,42,43).
Metabolic balance studies showed that
BPA residues were mainly excreted through
the digestive tract, in accordance with previ-
ous works carried out in rats (3,34,35). At 24
hr, 21% and 6% of the radioactivity injected
to pregnant mice had been excreted in feces
and urine, respectively; the digestive tract and
its content accounting for an additional 45%.
The total amount of radioactivity recovered
from gall bladders represented less than 2%
of the dosage. Because animals were not fed
during the 24-hr experiment, we assume that
significant gall bladder content emptying into
the duodenum did not occur. It is possible
that a large part of the BPA residues recov-
ered in feces and digestive tracts had actually
been directly secreted by the intestine. Such a
mechanism has already been demonstrated
for other xenobiotics (47,48). It cannot be
ruled out that the enterohepatic cycling
kinetics of BPA may have been modified by
the fact that the animals had not been fed
during the experiment. However, previous
statements that BPA residues undergo exten-
sive biliary excretion (9,43,49) deserve more
investigation, particularly in mice.
Measured blood radioactivity levels aver-
aged 2–4 ng/g of BPA equivalent in pregnant
mice, which is related to the use of a very low
dose of BPA. No direct comparison of these
results can be established with pharmaco-
kinetic data obtained from rodents dosed in
the high microgram per kilogram range (42) or
the milligram per kilogram range (9,35,42,43).
Results 0.5 hr after BPA injection showed that
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Table 5. Qualitative analysis of the radioactivity extracted from maternal plasma, liver, placenta, amniotic fluid, and fetuses for lot I, II, and III mice dosed
subcutaneously with 25 µg/kg 3H-BPA.
GlcA-BPA-OH GlcA-BPA-Glc Metabolite F GlcA-BPA BPA Othersa
Rt 11.5 ng/g % 17.5 ng/g % 24.0 ng/g % 25.0 ng/g % 33.5 ng/g % %
Maternal plasma
0.5 hr 0.07 ± 0.01 3 0.11 ± 0.02 4 0.11 ± 0.02 4 1.01 ± 0.19 39 1.06 ± 0.19 41 9
2 hr 0.02 ± 0.01 2 0.03 ± 0.01 4 0.03 ± 0.01 4 0.55 ± 0.14 63 0.15 ± 0.04 17 10
24 hr 0.04 ± 0.04 20 0 0 0.13 ± 0.05 65 0 15
Placenta
0.5 hr 0 0 0.46 ± 0.48 2 5.50 ± 4.24 25 15.98 ± 12.02 72 1
2 hr 0.03 ± 0.02 1 0.04 ± 0.03 1 0.37 ± 0.07 7 3.13 ± 2.34 62 1.32 ± 0.95 26 3
24 hr 0.05 ± 0.04 5 0.04 ± 0.02 4 0.64 ± 0.19 59 0.21 ± 0.22 19 0.06 ± 0.04 6 6
Fetus
0.5 hr 0.05 ± 0.03 1 0.04 ± 0.04 0 0.46 ± 0.27 5 3.83 ± 2.65 44 4.20 ± 2.16 49 1
2 hr 0.02 ± 0.02 1 0.01 ± 0.02 0 0.37 ± 0.22 13 1.93 ± 0.45 66 0.48 ± 0.55 16 3
24 hr 0.01 ± 0.01 1 0 0.11 ± 0.07 13 0.51 ± 0.12 60 0.13 ± 0.16 15 2
Amniotic fluid
0.5 hr 0.10 ± 0.14 1 0.19 ± 0.14 2 0.09 ± 0.13 1 8.17 ± 6.55 83 0.90 ± 0.89 9 4
2 hr 0.06 ± 0.03 1 0.07 ± 0.03 1 0.26 ± 0.15 5 4.82 ± 4.81 88 0.10 ± 0.07 2 2
24 hr 0.13 ± 0.05 8 0.01 ± 0.02 1 0.37 ± 0.09 24 0.70 ± 0.13 44 0.03 ± 0.03 2 20
Maternal liver
0.5 hr 0.12 ± 0.12 0 0.18 ± 0.24 0 6.22 ± 1.75 18 12.90 ± 2.81 37 10.85 ± 2.77 31 12
2 hr 0.08 ± 0.08 1 0.77 ± 0.25 8 2.16 ± 0.91 20 4.95 ± 1.82 45 1.51 ± 0.97 13 13
24 hr 0.16 ± 0.14 2 0.35 ± 0.13 7 0.99 ± 0.42 16 2.56 ± 1.62 36 1.72 ± 1.18 23 17
Results are expressed in nanograms per gram and as a percentage of the extracted radioactivity for the major compounds detected. 
aSum of all unlisted metabolites.
when administered through a parenteral route,
BPA was readily absorbed and distributed and
was found in ovaries, uterus, and fetuses.
Radioactivity levels decreased quickly, and the
amount of BPA residues detected at 2 and 24
hr were not significantly different. At 24 hr,
the highest concentration of residue was meas-
ured in the liver (12 ng/g), whereas less than
1 ng/g was detected in fat. The main difference
between samples collected at 2 and 24 hr was
qualitative; the latter ones contained a greater
proportion of volatile radioactivity that could
be a result of tritium exchange and/or related
to the metabolic breakdown of BPA into very
small molecules. For both time points, the
amount of extractable residues was higher in
livers, placentas, fetuses, and amniotic fluids
than in the corresponding plasmas.
Fecal radioactivity was mainly associated
with unchanged BPA, although traces of
HO3S-BPA and HO-BPA were detected.
Bile residues mainly consisted of GlcA-BPA.
Intestinal bacteria are often responsible for
the deconjugation of biliary glucuronides
into the parental xenobiotic (50), and indeed
most of the fecal radioactivity was detected as
unchanged BPA. However, digestive tract
extractions and subsequent radio-chromato-
graphic analyses not only demonstrated the
presence of BPA and GlcA-BPA, but also that
of another major metabolite whose struc-
ture was that of a dehydrated glucuronide 
conjugate of BPA (GlcA DH-BPA). To our
knowledge, the dehydration of a glucuronide
conjugate by mammalian biotransformation
systems or bacterial enzymes has never been
documented. However, both NMR and MS
experiments, including tritium/deuterium
exchange experiments unequivocally sup-
ported this structural characterization. In
terms of biologic activity, it is now well estab-
lished that GlcA-BPA is a far less potent
estrogen than BPA itself (39,41). The estro-
genic potency of the corresponding dehy-
drated conjugate (GlcA DH-BPA) is
unknown, but this major intestinal metabo-
lite was only detected in trace amounts in all
other tissues examined during this study.
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Figure 6. ESI-MSn analyses for metabolite F isolated from fetus extracts: mass spectra recorded in negative (A) and positive (B) ionization modes. A: MS, MS2 606,
and MS3 385; B: MS, MS2 608, MS3 204, and MS4 186 spectra.
The two major urinary metabolites
detected by radio-HPLC were GlcA-BPA, as
already evidenced in rat (3,34,35), and a newly
identified GlcA conjugate of hydroxylated
BPA, in which the hydroxylation takes place
on one of the methyl groups of BPA (GlcA-
BPA-OH). Its corresponding aglycone was not
detected. However, this metabolite is of poten-
tial interest because its structure would not
exclude estrogenic activity. Only a low amount
of unchanged BPA was detected, whatever the
BPA dosage or administration route. Several
double-conjugated metabolites of BPA were
characterized from urine. Two of them
(metabolites 22c and 22d), also identified from
liver extracts, were conjugates of methoxylated
BPA, which supports the results of previous in
vitro studies in rats (38) and humans (39) indi-
cating an aromatic hydroxylation of BPA into
catechol-BPA (3-hydroxy-BPA). The present
results demonstrate that this metabolic path-
way does exist in vivo. Catechol-BPA is a reac-
tive compound able to bind to DNA in vitro
(33), possibly following the formation of BPA-
o-quinone. In CD1 mice, this compound was
excreted in urine after being methylated (very
likely by catechol-O-methyl-transferase) and
conjugated. The existence of this metabolic
route was also supported by the identification
in digestive tract extracts of two structurally
close metabolites (22a and 22b). In vivo bio-
transformation of BPA into 3-hydroxy-BPA
may explain the formation of part of the
unextractable residues detected in tissues, but
is not expected to enhance the biologic activ-
ity of BPA, as this metabolite is supposed to
be a less potent estrogen than BPA (38,39).
The use of [3H]-BPA enabled a precise
monitoring of the residues present in livers,
plasma, and reproductive tracts of mothers, as
well as in fetuses. Radio-chromatograms
obtained for all these tissues were qualitatively
similar. Calculations based on the respective
proportions of extractable radioactivity and
direct MS structural characterization from
fetus extracts led to the quantification of the
three major metabolites, namely GlcA-BPA,
metabolite F, and unchanged BPA. It should
be stressed that regardless of the matrix assayed,
we found no qualitative difference between
mice dosed by subcutaneous or oral route. BPA
bioavailability was indeed lower when adminis-
tered orally, but in our opinion the differences
previously observed in rat for the respective
plasmatic radio-chromatograms (35) depend
not on the route of administration but on the
sensitivity of the applied methods.
The passage of BPA through the placental
barrier was demonstrated, corroborating previ-
ous results obtained in rats fed with a high oral
dosage of BPA (9,44). In CD1 mice, the trans-
portation of BPA into fetuses occurred rapidly,
as shown by its hepatic, plasmatic and fetal
concentrations at 0.5 hr (about 10, 1, and 4
ng/g, respectively). At this time point, calcu-
lated GlcA-BPA concentrations in the fetus
were similar to that of unchanged BPA. A
recent publication suggested that GlcA-BPA
could not cross the placental barrier in a rat
model (36). Although our data do not rule
out the possibility that GlcA-BPA may cross
the placental barrier in CD1 mice, it is likely
that its presence in fetal tissue is due to fetal
glucuronidation, as the GlcA-BPA concentra-
tion in amniotic fluids was always far above
that of unchanged BPA. In near-term
rodents, both fetal glucuronidation and
hydroxylations have previously been strongly
hypothesized for DES, a potent synthetic
estrogenic compound (51). Hydroxylated
BPA metabolites were not identified in fetus
extracts of CD1 mice, but their formation
cannot be ruled out, because the production
of catechol-BPA may partly explain that of
bound residues (at 24 hr, 0.25 ng/g of the
fetal radioactivity was not extractable).
Though BPA is a far less potent estrogen than
DES, the two compounds, which share some
structural characteristics, also share metabolic
similarities in rodents. Moreover, in pregnant
female rats administered a parenteral dosage of
DES, fetal residual levels were 2–3 times
greater than those measured in the mother’s
blood (51); there results are comparable to
those found in the present study for CD1 mice
dosed with BPA.
Metabolite F was identified as a disaccha-
ride conjugate of BPA. Though only detected
in trace amounts in plasma 24 hr after BPA
injection, it accounted for a large proportion
of the radioactivity detected in fetuses (10%),
maternal livers (20%), amniotic fluid (20%),
and placentas (60%). The metabolic pathway
leading to the formation of metabolite F and
the tissue(s) where it is synthesized remains
unknown. Metabolite F may result from the
conjugation of GlcA-BPA with N-acetyl-
galactosamine. However, the conjugation of
the sugar moiety of a conjugated xenobiotic by
a second sugar is a common metabolic process
only in plants. Very few examples of conjuga-
tion to an acetylated sugar have been reported.
Interestingly, one of the compounds for which
a conjugation to N-acetyl-glucosamine (an iso-
mer of N-acetyl-galactosamine) has been
demonstrated is estrone (isolated from preg-
nant women’s bile) (52); the double conjuga-
tion of the molecule occurs at two different
locations of the molecule. Thus, similarities
also exist between the metabolic pathways of
BPA and that of natural estrogens. It is worth
noting that GlcA/N-acetyl-galactosamine is the
repeating disaccharide found in the gly-
cosaminoglycan moiety (chondroitin sulfate,
dermatan sulfate) of proteoglycans, which are
major constituents of the extracellular matrix.
The biologic significance of the formation of
metabolite F and its possible connection with
the synthesis of proteoglycans requires further
investigation.
We performed this study to understand
more precisely the mechanism underlying the
low-dose effects of BPA. Understanding the
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Figure 7. Radio-chromatographic analysis of
approximately 3,000 disintegrations per minute
(dpm) (50 Bq) of metabolite F incubated with N-
acetyl galactosaminidase, fortified with an identi-
cal amount of metabolite F that was not submitted
to enzymatic deconjugation.
Figure 8. Proposed chemical structure and fragmentation pathways for metabolite F under both positive
(+) and negative (–) ESI.
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fate of BPA in mammalian animal models is
necessary to achieve a sound risk assessment
for this compound. Excreta and tissue analy-
ses, including fetuses, have clearly shown that
the metabolic pathways of BPA are more
complex than previously thought. GlcA-BPA
is indeed a major metabolite of BPA, but sev-
eral other metabolites have been characterized
in the present study, among which are several
uncommon structures such as Glc conjugates,
dehydrated glucuronides, and a disaccharide,
which represent a large part of the fetal and
hepatic radioactivity. None of these metabo-
lites is expected to possess an enhanced estro-
genic potency, suggesting that the estrogenic
effect of BPA derives from the parental com-
pound. However, these BPA metabolites have
yet to be tested for estrogen activity. A recent
study reported that BPA was transformed
into a potent estrogenic metabolite by Wistar
rat liver S9 fractions; however, its chemical
structure was not revealed (53). On the basis
of the chromatographic behavior of this com-
pound, we conclude it is not detected in CD1
mice in vivo. It is unknown whether the
absence of this metabolite is caused by lack of
synthesis or efficient transformation into
more polar compounds.
The results reported here support the
hypothesis that the endocrine disruptor activity
of BPA, if due exclusively to its estrogenic activ-
ity, could be mainly attributed to the parent
compound. BPA easily crosses the placental
barrier and is present both in fetuses and in the
reproductive tract of mothers. In addition, the
in vivo characterization of several metabolites
suggests that this xenoestrogen could be metab-
olized into reactive intermediates. The meta-
bolic fate of BPA should be thoroughly studied
in mammals, including humans, to understand
the biologic consequences of exposure.
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